Epizyme Inc (EPZM)

7.70
NASDAQ : Health Care
Prev Close 7.54
Day Low/High 7.48 / 7.85
52 Wk Low/High 7.36 / 21.27
Avg Volume 391.80K
Exchange NASDAQ
Shares Outstanding 57.96M
Market Cap 437.00M
EPS -3.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.

Epizyme Initiates Collaboration On Combination Trial Of Tazemetostat And Tecentriq™ (atezolizumab) For Treatment Of Non-Hodgkin Lymphoma

Epizyme Initiates Collaboration On Combination Trial Of Tazemetostat And Tecentriq™ (atezolizumab) For Treatment Of Non-Hodgkin Lymphoma

Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, announced today it has entered into a collaboration agreement with Genentech, a member of...

First Week of EPZM February 2017 Options Trading

First Week of EPZM February 2017 Options Trading

Investors in Epizyme Inc. saw new options begin trading this week, for the February 2017 expiration.

Trade-Ideas: Epizyme (EPZM) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Epizyme (EPZM) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Epizyme (EPZM) as a weak on high relative volume candidate

Epizyme Reports Early Data From Global Phase 2 Trial Of Tazemetostat In Non-Hodgkin Lymphoma At ASH Lymphoma Biology Meeting

Epizyme Reports Early Data From Global Phase 2 Trial Of Tazemetostat In Non-Hodgkin Lymphoma At ASH Lymphoma Biology Meeting

Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today reported preliminary data from its ongoing, global Phase 2 clinical trial of orally administered...

Epizyme (EPZM): Today's Weak On High Volume Stock

Epizyme (EPZM): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Epizyme (EPZM) as a weak on high relative volume candidate

Trade-Ideas: Epizyme (EPZM) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Epizyme (EPZM) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Epizyme (EPZM) as a strong on high relative volume candidate

Epizyme To Present Data From The Tazemetostat Non-Hodgkin Lymphoma Program At American Society For Hematology Meeting On Lymphoma Biology

Epizyme To Present Data From The Tazemetostat Non-Hodgkin Lymphoma Program At American Society For Hematology Meeting On Lymphoma Biology

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that data from four abstracts from the Company's clinical development...

Epizyme Announces First Quarter 2016 Financial Results And Provides Update On Execution Against Multi-Year Company Vision

Epizyme Announces First Quarter 2016 Financial Results And Provides Update On Execution Against Multi-Year Company Vision

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today reported recent business and program highlights as part of its multi-year vision and...

Epizyme Announces Collaboration With Lymphoma Study Association To Evaluate Combination Of Tazemetostat With R-CHOP In Front-line Non-Hodgkin Lymphoma

Epizyme Announces Collaboration With Lymphoma Study Association To Evaluate Combination Of Tazemetostat With R-CHOP In Front-line Non-Hodgkin Lymphoma

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has entered into a collaboration agreement with the Lymphoma Study...

Epizyme Continues To Build Senior Leadership Team With Appointment Of Matthew Ros As Chief Operating Officer

Epizyme Continues To Build Senior Leadership Team With Appointment Of Matthew Ros As Chief Operating Officer

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has expanded its senior leadership team with the addition of...

Epizyme Announces FDA Acceptance Of Investigational New Drug Application For Tazemetostat In Mesothelioma

Epizyme Announces FDA Acceptance Of Investigational New Drug Application For Tazemetostat In Mesothelioma

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that the U.

Epizyme To Report First Quarter 2016 Financial Results And Provide Corporate Update On May 9, 2016 And To Participate In Upcoming May Conferences

Epizyme To Report First Quarter 2016 Financial Results And Provide Corporate Update On May 9, 2016 And To Participate In Upcoming May Conferences

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, announced today that management will host a conference call and live audio webcast on...

Commit To Buy Epizyme At $7.50, Earn 20.4% Annualized Using Options

Commit To Buy Epizyme At $7.50, Earn 20.4% Annualized Using Options

Investors eyeing a purchase of Epizyme Inc. shares, but cautious about paying the going market price of $10.84/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Epizyme Broadens Executive Leadership Team With Experienced New Officer And Senior Management

Epizyme Broadens Executive Leadership Team With Experienced New Officer And Senior Management

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has expanded its executive leadership team with the addition of...

Epizyme Presents Data From Tazemetostat Clinical Pharmacology Studies At American Association For Cancer Research Annual Meeting 2016

Epizyme Presents Data From Tazemetostat Clinical Pharmacology Studies At American Association For Cancer Research Annual Meeting 2016

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today presented data from clinical studies that investigated the effect of food...

Epizyme (EPZM) Strong On High Relative Volume Today

Epizyme (EPZM) Strong On High Relative Volume Today

Trade-Ideas LLC identified Epizyme (EPZM) as a strong on high relative volume candidate

Epizyme To Present New Data In Support Of Tazemetostat Clinical Development Program

Epizyme To Present New Data In Support Of Tazemetostat Clinical Development Program

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced that data from five accepted abstracts of tazemetostat (EPZ-6438), its...

Epizyme Announces 2015 Financial Results And Financial Guidance

Epizyme Announces 2015 Financial Results And Financial Guidance

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today highlighted certain 2015 and recent accomplishments and reported financial results...

Epizyme Unveils Corporate Strategy To Guide Efforts Over Next Five Years

Epizyme Unveils Corporate Strategy To Guide Efforts Over Next Five Years

Epizyme, Inc., (NASDAQ:EPZM) a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today announced its corporate vision and strategy through 2020.

5 Stocks Set to Soar on Bullish Earnings

5 Stocks Set to Soar on Bullish Earnings

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

Epizyme To Report 2015 Financial Results And Provide Business Updates On March 9, 2016

Epizyme To Report 2015 Financial Results And Provide Business Updates On March 9, 2016

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today it will host a conference call on Wednesday, March 9, 2016 at 8:00 a.

Short Interest Increases 24.6% For EPZM

Short Interest Increases 24.6% For EPZM

The most recent short interest data has been released by the NASDAQ for the 02/12/2016 settlement date, which shows a 900,374 share increase in total short interest for Epizyme Inc. , to 4,567,956, an increase of 24.55% since 01/29/2016.

Epizyme Is Now Oversold (EPZM)

Epizyme Is Now Oversold (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Epizyme Execs Pocket Cheap Stock Options, Tone Deaf to Shareholder Pain

Epizyme Execs Pocket Cheap Stock Options, Tone Deaf to Shareholder Pain

With new stock option grants this week, Epizyme executives are sending an ugly message to aggrieved shareholders: We don't mind profiting from your pain.

Epizyme Announces Tazemetostat Granted Orphan Drug Designation For Malignant Rhabdoid Tumors By U.S. FDA

Epizyme Announces Tazemetostat Granted Orphan Drug Designation For Malignant Rhabdoid Tumors By U.S. FDA

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today that the United States Food and Drug Administration (FDA) has...

Epizyme To Present At Upcoming Investor Conferences

Epizyme To Present At Upcoming Investor Conferences

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that the Company will participate in four investor conferences in February:...